Houston, Texas 77030


A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies

Study summary:

This study has two parts. There will be a single dose of NJH395 in the first part and multiple doses of NJH395 in the second part. After the first part is completed, the second part may open.


Key Inclusion Criteria: - Patient must have known histologically or cytologically confirmed and documented HER2-positive solid tumor excluding patients with breast cancer - Advanced/metastatic cancer with measurable disease as determined by RECIST v.1.1 who have progressed or are intolerant to all approved therapies known to confer clinical benefit. - Eastern Cooperative Oncology Group (ECOG) performance status ≤2. - Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy prior to therapy, and during therapy on this study. Key Exclusion Criteria: - History of severe hypersensitivity to any ingredient of study drug, trastuzumab or other monoclonal antibody. - Patients previously treated with TLR 7/8 agonist. - Impaired cardiac function or history of clinically significant cardiac disease - Active, known or suspected autoimmune disease. - Human Immunodeficiency virus (HIV) infection - History of or current interstitial lung disease or pneumonitis Grade 2 or greater. - Discontinued prior checkpoint inhibitor due to a checkpoint inhibitor related toxicity. - Currently receiving medications known to cause Torsades de Pointe that cannot be discontinued 7 days prior to starting treatment Other protocol defined inclusion/exclusion criteria may apply.



Primary Contact:

Novartis Pharmaceuticals
Phone: 1-888-669-6682
Email: novartis.email@novartis.com

Backup Contact:

Novartis Pharmaceuticals
Phone: +41613241111

Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.